Metastatic salivary duct carcinoma in cardiac and pleural effusions: A case report with immunocytochemical analysis for androgen receptor and HER2.
androgen receptor
cardiac effusion
human epidermal growth factor receptor 2
pleural effusion
salivary duct carcinoma
Journal
Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
01
08
2018
accepted:
15
10
2018
entrez:
19
1
2019
pubmed:
19
1
2019
medline:
19
1
2019
Statut:
ppublish
Résumé
Salivary duct carcinoma (SDC) is a relatively rare highly aggressive salivary gland tumor. Although SDC shows frequent lymph node and distant metastases, the presence of neoplastic cells in the pleural effusion is extremely rare. In this report, we describe the first documented cytological case of metastatic SDC in cardiac and pleural effusions with immunocytochemical analyses for androgen receptor (AR) and human epidermal growth factor receptor (HER)2. A 52-year-old Japanese male developed cardiac tamponade and respiratory discomfort after surgery and chemo-radiation therapy for SDC of the right submandibular gland. Aspiration of the cardiac and pleural effusions was performed. The Papanicolaou-stained cytological specimens of cardiac and pleural effusions showed that numerous small ball-like or papillary structures were present in an inflammatory background. The neoplastic cells had rich granular cytoplasm and large round to oval nuclei containing conspicuous nucleoli. Immunocytochemical analyses clearly demonstrated positivity for AR and strong membranous expression of HER2 in the neoplastic cells. Accordingly, a cytodiagnosis of metastatic SDC was made. Recently, HER2-targeted or AR deprivation therapy have been introduced for patients with SDC, therefore, determination of expression profiles of AR and HER2 may be crucial for developing a treatment strategy for patients with metastatic SDC. According to the results of the present report, immunocytochemical analyses for AR and HER2 in the effusion specimens may be useful for determination of a treatment strategy for patients with metastatic SDC.
Identifiants
pubmed: 30655980
doi: 10.3892/mco.2018.1747
pii: MCO-0-0-1747
pmc: PMC6313956
doi:
Types de publication
Journal Article
Langues
eng
Pagination
78-82Références
Cancer. 2001 Oct 25;93(5):344-50
pubmed: 11668470
Diagn Cytopathol. 2006 Jul;34(7):491-4
pubmed: 16783770
Hum Pathol. 2012 Jul;43(7):1003-11
pubmed: 22154362
Histopathology. 2012 Oct;61(4):629-43
pubmed: 22882517
Oncologist. 2013;18(3):294-300
pubmed: 23429737
Cytojournal. 2014 Feb 15;11:4
pubmed: 24738005
Head Neck. 2016 May;38(5):724-31
pubmed: 25522335
Cytojournal. 2016 Jun 10;13:13
pubmed: 27382407
Oncotarget. 2017 Aug 2;8(35):59023-59035
pubmed: 28938615
Diagn Cytopathol. 2018 May;46(5):429-433
pubmed: 29205961
Acta Cytol. 1987 Mar-Apr;31(2):85-97
pubmed: 3469856
Acta Cytol. 1983 Sep-Oct;27(5):525-8
pubmed: 6578650
Diagn Cytopathol. 1994;11(1):47-51
pubmed: 7956660
Respir Med. 1997 Mar;91(3):169-70
pubmed: 9135856